The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Open accessAbstract
Somatostatin receptor imaging (SRI) with [111 In-DTPA 0]octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer radiolabeled somatostatin analogs which can be used in positron emission tomography (PET) imaging, and which have a higher affinity for the somatostatin receptor, especially receptor subtype-2, have been developed. It would be desirable, however, if one radiolabeled analog became the new standard for PET imaging, because the current application of a multitude of analogs implies a fragmented knowledge on the interpretation of the images that are obtained in clinical practice. In our view, the most likely candidates for such a universal PET tracer for SRI are [68 Ga-DOTA 0,Tyr 3]octreotate or [68 Ga-DOTA 0,Tyr 3]octreotide. Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111 In-, 90 Y-, or 177 Lu-labeled somatostatin analogs that have been used for peptide receptor radionuclide therapy (PRRT). The results that were obtained with [90 Y-DOTA 0,Tyr 3]octreotide and [177 Lu-DOTA 0,Tyr 3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of this therapy are few and mild, and the median duration of the therapy response for these radiopharmaceuticals is 30 and 40 months respectively. The patients' self-assessed quality of life increases significantly after treatment with [177 Lu-DOTA 0,Tyr 3]octreotate. Lastly, compared to historical controls, there is a benefit in overall survival of several years from the time of diagnosis in patients treated with [177 Lu-DOTA 0,Tyr 3]octreotate. These data compare favorably with the limited number of alternative treatment approaches. If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,196
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Self-citationKwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Self-citationReubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Moertel, C. G., Hanley, J. A., & Johnson, L. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011203032101 · Cited by 659
Reubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Kulke, M. H., Lenz, H.-J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9020 · Cited by 623
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Hofmann, M., Maecke, H., Börner, A., Weckesser, E., Schöffski, P., Oei, M., Schumacher, J., Henze, M., Heppeler, A., Meyer, G., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100639 · Cited by 544
Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., Schilling, T., Haufe, S., Herrmann, T., & Haberkorn, U. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0450-1 · Cited by 506
Faiss, S., Pape, U.-F., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W., Riecken, E. O., & Wiedenmann, B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.142 · Cited by 501
Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
Janson, E. T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., & öberg, K. (1997) · Annals of Oncology · doi:10.1023/a:1008215730767 · Cited by 455
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A. R., & Mueller‐Brand, J. (2002) · PubMed · Cited by 445
Gibril, F., Reynolds, J. C., Doppman, J. L., Chen, C. C., Venzon, D. J., Termanini, B., Weber, H. C., Stewart, C. A., & Jensen, R. T. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00005 · Cited by 440
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 435
Self-citationEuropean Journal of Nuclear Medicine and Molecular Imaging
(2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/259.1619-7089 · Cited by 430
Kwekkeboom, D. J., Bakker, W. H., Kam, B. L., Teunissen, J. J. M., Kooij, P. P. M., de Herder, W. W., Feelders, R. A., van Eijck, C. H. J., de Jong, M., Srinivasan, A., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1050-8 · Cited by 424
Self-citationYttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maecke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 420
Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., & Mueller-Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396
Kwekkeboom, D. J., Mueller‐Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S. A., Kvols, L. K., O’Dorisio, T. M., Valkema, R., Bodei, L., Chinol, M., et al. (2005) · PubMed · Cited by 367
Self-citationSun, W., Lipsitz, S., Catalano, P., Mailliard, J. A., & Haller, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.616 · Cited by 357
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
de Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A. P., Bakker, W. H., Smith, C., Pauwels, S., & Krenning, E. P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31027 · Cited by 346
Self-citationA phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603419 · Cited by 317
Valkema, R., Pauwels, S., Kvols, L. K., Barone, R., Jamar, F., Bakker, W. H., Kwekkeboom, D. J., Bouterfa, H., & Krenning, E. P. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.01.001 · Cited by 313
Self-citationBodei, L., Cremonesi, M., Zoboli, S., Grana, C., Bartolomei, M., Rocca, P., Caracciolo, M., Mäcke, H. R., Chinol, M., & Paganelli, G. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1023-y · Cited by 305
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., & McCarthy, K. E. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31769 · Cited by 279
Ambrosini, V., Tomassetti, P., Castellucci, P., Campana, D., Montini, G., Rubello, D., Nanni, C., Rizzello, A., Franchi, R., & Fanti, S. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0769-2 · Cited by 266
Epidemiology and survival in patients with carcinoid disease in the Netherlands
Quaedvlieg, P. F. H. J., Visser, O., Lamers, C. B. H. W., Janssen-Heijen, M. L. G., & Taal, B. G. (2001) · Annals of Oncology · doi:10.1023/a:1012272314550 · Cited by 260
Mazzaglia, P. J., Berber, E., Milas, M., & Siperstein, A. E. (2007) · Surgery · doi:10.1016/j.surg.2007.01.036 · Cited by 256
[123I]Metaiodobenzylguanidine and[111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas1
van der Harst, E., de Herder, W. W., Bruining, H. A., Bonjer, H. J., de Krijger, R. R., Lamberts, S. W. J., van de Meiracker, A. H., Boomsma, F., Stijnen, T., Krenning, E. P., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7238 · Cited by 253
Self-citationTreatment of the carcinoid tumor and the malignant carcinoid syndrome.
Moertel, C. G. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.727 · Cited by 245
111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial
Virgolini, I., Britton, K., Buscombe, J., Moncayo, R., Paganelli, G., & Riva, P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31565 · Cited by 243
Lebtahi, R., Cadiot, G., Sarda‐Mantel, L., Daou, D., Faraggi, M., Petegnief, Y., Mignon, M., & Guludec, D. L. (1997) · PubMed · Cited by 240
Bajetta, E., Catena, L., Procopio, G., De Dosso, S., Bichisao, E., Ferrari, L., Martinetti, A., Platania, M., Verzoni, E., Formisano, B., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0306-6 · Cited by 240
Koopmans, K. P., Neels, O. C., Kema, I. P., Elsinga, P. H., Sluiter, W. J., Vanghillewe, K., Brouwers, A. H., Jager, P. L., & de Vries, E. G. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1126 · Cited by 238
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study
Koopmans, K. P., de Vries, E. G., Kema, I. P., Elsinga, P. H., Neels, O. C., Sluiter, W. J., van der Horst-Schrivers, A. N., & Jager, P. L. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70801-4 · Cited by 237
Zimmer, T., Stölzel, U., Bäder, M., Koppenhagen, K., Hamm, B., Buhr, H., Riecken, E. O., & Wiedenmann, B. (1996) · Gut · doi:10.1136/gut.39.4.562 · Cited by 223
Rich, T. A., Shepard, R. C., & Mosley, S. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.009 · Cited by 212
de Jong, M., Breeman, W. A., Bakker, W., Kooij, P. P. M., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M. A., Erion, J. L., et al. (1998) · PubMed · Cited by 209
Self-citationJanson, E. T., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083916 · Cited by 204
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Forrer, F., Krenning, E. P., Kooij, P. P., Bernard, B. F., Konijnenberg, M., Bakker, W. H., Teunissen, J. J. M., de Jong, M., van Lom, K., de Herder, W. W., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1072-6 · Cited by 201
Self-citationCheng, P. N. M., & Saltz, L. B. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990915)86:6<944::aid-cncr8>3.0.co;2-p · Cited by 199
Teunissen, J. J. M., Kwekkeboom, D. J., & Krenning, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.016 · Cited by 197
Self-citationThe antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Ducreux, M. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02003-7 · Cited by 196
Arnold, R., Müller, H., Schade-Brittinger, C., Rinke, A., Klose, K., Barth, P., Wied, M., Mayer, C., Aminossadati, B., & PROMID Study Group (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4508 · Cited by 192
Esser, J. P., Krenning, E. P., Teunissen, J. J. M., Kooij, P. P. M., van Gameren, A. L. H., Bakker, W. H., & Kwekkeboom, D. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0172-9 · Cited by 179
Self-citationWehrmann, C., Senftleben, S., Zachert, C., Müller, D., & Baum, R. P. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2006.325 · Cited by 177
Octreotide scintigraphy for the detection of paragangliomas.
Kwekkeboom, D. J., van Urk, H., Pauw, B. K. H., et al. (1993) · PubMed · Cited by 168
Self-citationGibril, F., Reynolds, J. C., Chen, C. C., Yu, F., Goebel, S. U., Serrano, J., Doppman, J. L., & Jensen, R. T. (1999) · PubMed · Cited by 159
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon, H. R., Goldsmith, S. J., Siegel, B. A., Silberstein, E. B., Krenning, E. P., Lang, O., & Donohoe, K. J. (2001) · PubMed · Cited by 140
Self-citationvan Essen, M., Krenning, E. P., Kam, B. L. R., de Herder, W. W., van Aken, M. O., & Kwekkeboom, D. J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0688-7 · Cited by 138
Self-citationde Keizer, B., van Aken, M. O., Feelders, R. A., de Herder, W. W., Kam, B. L. R., van Essen, M., Krenning, E. P., & Kwekkeboom, D. J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0691-z · Cited by 134
Self-citationKindler, H. L., & Shulman, K. L. (2001) · Current Treatment Options in Oncology · doi:10.1007/s11864-001-0068-7 · Cited by 133
Belhocine, T., Foidart, J. B., Rigo, P., Najjar, F., Thiry, A., Quatresooz, P., & Hustinx, R. (2002) · Nuclear Medicine Communications · doi:10.1097/00006231-200208000-00005 · Cited by 130
Chinol, M., Bodei, L., Cremonesi, M., & Paganelli, G. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31563 · Cited by 127
Hubalewska–Dydejczyk, A., Fröss‐Baron, K., Mikołajczak, R., Maëcke, H. R., Huszno, B., Pach, D., Sowa‐Staszczak, A., Janota, B., Szybiński, P., & Kulig, J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0113-7 · Cited by 114
A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
Ansell, S. M., Pitot, H. C., Burch, P. A., Kvols, L. K., Mahoney, M. R., & Rubin, J. (2001) · Cancer · doi:10.1002/1097-0142(20010415)91:8<1543::aid-cncr1163>3.0.co;2-n · Cited by 107
90Y–DOTA– D ‐Phe1–Try3– octreotide in therapy of neuroendocrine malignancies
Paganelli, G., Bodei, L., Handkiewicz-Junak, D., Rocca, P. A., Papi, S., Sierra, M. L., Gatti, M., Chinol, M., Bartolomei, M., Fiorenza, M., et al. (2002) · Biopolymers · doi:10.1002/bip.10349 · Cited by 104
Wong, J. Y. C., Shibata, S., Williams, L. E., Kwok, C. S., Liu, A., Chu, D. Z. J., Yamauchi, D. M., Wilczynski, S. P., Iklé, D. N., Wu, A. M., et al. (2003) · PubMed · Cited by 97
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid
Bukowski, R. M., Tangen, C. M., Peterson, R. F., Fleming, T. R., Taylor, S. A., Rinehart, J. J., Eyre, H. J., Rivkin, S. E., Macdonald, J. S., & A Southwest Oncology Group Study (1994) · Cancer · Cited by 90
Lebtahi, R., Cloirec, J. L., Houzard, C., Daou, D., Sobhani, I., Sassolas, G., Mignon, M., Bourguet, P., & Guludec, D. L. (2002) · PubMed · Cited by 89
Clinical and In vitro Studies of Imatinib in Advanced Carcinoid Tumors
Yao, J. C., Zhang, J. X., Rashid, A., Yeung, S. J., Szklaruk, J., Hess, K. R., Xie, K., Ellis, L. M., Abbruzzese, J. L., & Ajani, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1618 · Cited by 88
Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET
Fanti, S., Ambrosini, V., Tomassetti, P., Castellucci, P., Montini, G. C., Allegri, V., Grassetto, G., Rubello, D., Nanni, C., & Franchi, R. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.01.010 · Cited by 83
Chemotherapy for Gastro-Enteropancreatic Endocrine Tumours
O’Toole, D., Hentic, O., Corcos, O., & Ruszniewski, P. B. (2004) · Neuroendocrinology · doi:10.1159/000080747 · Cited by 82
Octreotide Scintigraphy for the Detection of Paragangliomas
Telischi, F. F., Bustillo, A., Whiteman, M. L. H., et al. (2000) · Otolaryngology · doi:10.1016/s0194-5998(00)70048-9 · Cited by 80
Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome
GRESZE, de Kerviler, É., Cadiot, G., et al. (1994) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00182352 · Cited by 74
Alkaline Phosphatase Predicts Survival in Patients with Metastatic Neuroendocrine Tumors
Clancy, T. E., Sengupta, T. P., Paulus, J. K., Ahmed, F., Duh, M. S., & Kulke, M. H. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9345-4 · Cited by 72
Adams, S., Baum, R. P., Hertel, A., Schumm-Draeger, P. M., Usadel, K.-H., & Hör, G. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050296 · Cited by 70
Gastroenteropancreatic Endocrine Tumours: Effect of Sandostatin® on Tumour Growth
Arnold, R., Benning, R., Neuhaus, C., et al. (2009) · Digestion · doi:10.1159/000201081 · Cited by 65
Duet, M., Sauvaget, E., Pételle, B., Rizzo, N., Guichard, J., Wassef, M., Cloirec, J. L., Herman, P., & Huy, P. T. B. (2003) · PubMed · Cited by 63
Kälkner, K. M., Janson, E. T., Nilsson, S. F., Carlsson, S., Öberg, K., & Westlin, J. E. (1995) · PubMed · Cited by 58
Andreyev, J. N., Scott-Mackie, P., Cunningham, D., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1486 · Cited by 46
Treatment of metastasized midgut carcinoids with dacarbazine.
Ritzel, U., Leonhardt, U., Stöckmann, F., et al. (1995) · PubMed · Cited by 43
Lugtenburg, P. J., Krenning, E. P., Valkema, R., Oei, H. Y., Lamberts, S. W. J., Eijkemans, M. J. C., van Putten, W. L. J., & Löwenberg, B. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02583.x · Cited by 41
Self-citationPeptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren
Baum, R. P., S�ldner, J., Schm�cking, M., & Niesen, A. (2004) · Der Onkologe · doi:10.1007/s00761-004-0771-7 · Cited by 31
Otolaryngology and head and neck surgery
Corbridge, R. (2009) · Oxford University Press eBooks · Cited by 28
Neijt, J. P., Lacave, A. J., Splinter, T. A. W., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.21 · Cited by 22
Cited by
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Self-citationZaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Self-citationGastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 578
Self-citationBodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2893-5 · Cited by 465
Self-citation
Metadata
- Authors
- Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2010-03
- Volume
- 17
- Issue
- 1
- Pages
- R53-R73
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2148617171
- Cited by
- 466
- References
- 82
- FWCI
- 16.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.